Novartis Ag (NVS) Cash from Discontinued Operations (2012 - 2023)

Novartis Ag has disclosed Cash from Discontinued Operations across 8 years of filings, most recently posting $74.0 million for Q3 2023.

• In Q3 2023, Cash from Discontinued Operations fell 83.41% year-over-year to $74.0 million; the TTM figure through Dec 2023 stood at $238.0 million (down 69.84% YoY), while the FY2023 annual figure was $238.0 million, down 80.12% from the prior year.
• Cash from Discontinued Operations came in at $74.0 million for Q3 2023 at Novartis Ag, up from $59.0 million in the prior quarter.
• In the past five years, Cash from Discontinued Operations ranged from a high of $499.0 million in Q2 2019 to a low of $59.0 million in Q2 2023.
• Average Cash from Discontinued Operations over 3 years is $229.1 million, with a median of $105.0 million recorded in 2023.
• Year-over-year, Cash from Discontinued Operations gained 16.05% in 2019 and slumped 83.41% in 2023.
• Over 3 years, Cash from Discontinued Operations stood at $499.0 million in 2019, then sank by 31.26% to $343.0 million in 2022, then plunged by 78.43% to $74.0 million in 2023.
• Per Business Quant data, the three most recent Cash from Discontinued Operations figures were $74.0 million in Q3 2023, $59.0 million in Q2 2023, and $105.0 million in Q1 2023.